Large-scale comparison of experimental adjuvants with herpes simplex virus vaccine reveals a correlation of protection with IgG2a and IgG2b responses

Journal of Medical Virology

Volumn 68, Issue 1, 2002, Pages 82-91

  Simms, John R ^a   Jennings, Roy ^a   Richardson, Vernon J ^b   Heath, Andrew W ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Adjuvant; Antibody; HSV

Indexed keywords

8 MERCAPTOGUANOSINE; ALUMINUM POTASSIUM SULFATE; COLECALCIFEROL; FREUND ADJUVANT; GALACTOSE OXIDASE; GAMMA INTERFERON; GERBU; GERBU M2; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; ISCOM; MONTANIDE ISA 51; MPL; PEPTIDE; PHOSPHORYL LIPID A; POLY(METHYL METHACRYLATE); PRASTERONE; SIALIDASE; STEAROYLTYROSINE; SUBUNIT VACCINE; TITERMAX; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; NONHUMAN; TOXICITY TESTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CERCOPITHECUS; COMPARATIVE STUDY; HUMAN; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; VACCINATION; VERO CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMAL; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; COMPARATIVE STUDY; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HUMAN; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; SUPPORT, NON-U.S. GOV'T; VACCINATION; VERO CELLS; ANIMALS; HUMANS;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0036021192     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10173     Document Type: Article

References (69)

1. Control of animal pain and distress in antibody production and infectious disease studies
2. Reduced antibody-dependent cellular cytotoxicity to Herpes Simplex Virus-infected cells of salivary polymorphonuclear leukocytes and inhibition of peripheral blood polymorphonuclear leukocyte cytotoxicity by saliva
3. Protection against lethal challenge of Balb/c mice by passive transfer of monoclonal antibodies to five glycoproteins of Herpes Simplex Virus type 2
4. Action of saponin on biological cell membranes
5. A comparison of commercially available adjuvants for use in research
6. A retrospective review of lesions associated with the use of Freund's adjuvant
7. Efficacy trial of an inactivated HSV-2 vaccine
8. Enhancement of IgG anti-carrier responses by IgG2 anti-hapten antibodies in mice
9. Studies on experimental adjuvanted influenza vaccines: Comparison of immune stimulating complexes (ISCOMs™) and oil-inwater vaccines
10. IgG2a restriction of murine antibodies elicited by viral infections
11. Virally induced modulation of murine IgG antibody subclasses
12. Comparison of Freund's and RIBI adjuvants for inducing antibodies to the synthetic antigen (TG)-AL in rabbits
13. Antibody responses and protection in mice immunized with herpes simplex virus type-1 antigen immune-stimulating complex preparations
14. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection
15. Cytotoxicity mediated by human Fc receptors for IgG
16. Vaccine potential of a Herpes Simplex Virus type 1 mutant with an essential glycoprotein deleted
17. The effect of paraffin oil and mycobacteria on antibody formation and sensitisation
18. Enhancement of systemic immune responses following oral administration of liposomes
19. Expression of seven Herpes Simplex Virus type 1 glycoproteins (gB, gC, gD, gE, gH and gI): Comparative protection against lethal challenge in mice
20. Adjuvants for human vaccines-current status, problems and future prospects
21. Adjuvants: A balance between toxicity and adjuvanticity
22. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems
23. Mineral-oil adjuvants and the immunization of laboratory animals
24. Receptors for IgG: Subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line
25. Antigen-presenting liposomes are effective in treatment of recurrent Herpes Simplex Virus genitalis in guinea pigs
26. IgG subtype is correlated with efficiency of passive protection and effector function of anti-Herpes Simplex Virus glycoprotein D monoclonal antibodies
27. Comparative studies of HSV-1 antigens solubilized from infected cells by using non-ionic or zwitterionic detergents
28. Pathogenesis of Herpes Simplex Virus in B cell suppressed mice: The relative roles of cell-mediated and humoral immunity
29. Incorporation of the major outer envelope protein of Neisseria gonorrhoeae in saponin lipid complexes (ISCOMs): Chemical analysis, some structural features and comparison of their immunogenicity with three other antigen delivery systems
30. On the structure of immune-stimulating saponin-lipid complexes (ISCOMs)
31. Activation of mouse complement by different classes of mouse antibody
32. Passive immune protection by Herpes Simplex Virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity
33. Correlation of functional properties of human diploid cell subsets and surface marker phenotypes using multiparameter analysis and flow cytometry
34. Evaluation of several adjuvants as alternatives to the use of Freund's adjuvant in rabbits
35. Comparison of adjuvants for immune potentiating properties and side effects in mice
36. Comparison of immune response potentiation and in vivo inflammatory effects of Freund's and RIBI adjuvants in mice
37. The requirement of lipids for the formation of immuno-stimulating complexes (ISCOMs)
38. Comparison of antibody response by use of synthetic adjuvant system and Freund's complete adjuvant in rabbits
39. IgG-mediated viral clearance in experimental infection with Herpes Simplex Virus type 1: Role for neutralisation and Fc-dependent functions but not C1 and C5 chemotaxis
40. Protection against zosteriform spread of Herpes Simplex Virus by monoclonal antibodies
41. Complement-immunoglobulin interactions
42. Activation of mouse complement by mouse monoclonal antibodies
43. Mechanism of virus-induced Ig subclass shifts
44. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus neutralising antibody when incorporated into liposomes
45. Role of Fc fragment in antibody-mediated recovery from ocular and subcutaneous Herpes Simplex Virus infections
46. Immune response to immunostimulating complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the external envelope glycoprotein (gp120)
47. Fc receptors
48. Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex type 1 infection
49. Reshaping human antibodies for therapy
50. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines
51. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in Guinea pigs
52. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix
53. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes
54. The biologic activities of guinea-pig antibodies. II. Modes of complement interaction with γ1 and γ2 immunoglobulins
55. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA
56. Role of antibody in primary and recurrent Herpes Simplex Virus infection
57. Use of Herpes Simplex Virus (HSV) Type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs
58. Local reactions of the saponin Quil A and a Quil A containing ISCOM measles vaccine after intramuscular injection of rats: A comparison with the effect of DPT-polio vaccine
59. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titers of binding antibodies and toxicity of the formulations
60. Comparison of conventional adjuvants and "adjuvant-free" monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinising hormone releasing hormone and avidin
61. An evaluation of distress following intraperitoneal immunization with Freund's adjuvant in mice
62. Vaccination of rabbits with a bovine herpes virus type 1 subunit vaccine: Adjuvant effect of ISCOMs
63. Chemie und biologie der saponine
64. Granuloma formation in normal guinea pigs injected intradermally with aluminium and zirconium compounds
65. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses
66. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates
67. A compendium of vaccine adjuvants and excipients
68. CpG DNA induces stronger immune responses with less toxicity than other adjuvants